少转移性前列腺癌（OmPCa）的特点是转移灶数量有限，局限于有限的器官范围，这给临床带来了独特的挑战。前列腺细胞减灭术（CRP）在治疗这一特定转移阶段中的作用已引起人们的关注，但仍存在争议。本研究旨在通过综合以往研究的结果并分析多中心回顾性队列数据来评估 CRP 在 OmPCa 中的有效性。我们重点评估总生存期 (OS)、无进展生存期 (PFS)、癌症特异性生存期 ( CSS）和去势抵抗性前列腺癌无癌生存期（CRPCFS）作为主要结局。还对 2008 年 1 月至 2018 年 6 月接受 CRP 治疗的 OmPCa 患者与仅接受雄激素剥夺疗法 (ADT) 的患者进行了多中心比较回顾性分析。我们收集并分析了患者人口统计、肿瘤特征、手术结果和生存指标的数据。定量分析包括18项研究（2项随机对照试验（RCT）和16项非RCT研究），共1733例寡转移性前列腺癌患者，这是目前同一课题研究中纳入样本数最多的一次。汇总分析表明，细胞减灭术与 OS 显着改善相关（风险比 [HR]：0.50，95% 置信区间 [CI]：0.40-0.60）、PFS（HR：0.39，95%[CI]：0.27-0.51）与非手术治疗相比，CSS（HR：0.44，95％[CI]：0.23-0.65）和CRPCFS（HR：0.48，95％[CI]：0.36-0.59）。此外，OS，PFS和CRPCFS显示在所有分析（RCT 和非 RCT）中，CRP 组的结果均较好。此外，在我们的多中心回顾性研究分析中，纳入了 64 例寡转移性前列腺癌患者，其中 32 例接受了 CRP（50%），32 例仅接受了 ADT（50%）。 %）。中位随访时间为40.1（18.9-51.3）个月。两个匹配队列之间的OS（P=0.0182）、PFS（P=0.0297）和CRPCFS（P=0.0125）有统计学差异。 ，我们观察到 8 例 (25%) 围手术期并发症，最常见的是尿失禁 (9.4%)。在 OmPCa 治疗方案中将 CRP 与 ADT 结合使用可显着提高患者的 OS、PFS 和无 CRPC 结局生存率，强调了这种手术方法在特定患者群体中的潜在益处。版权所有 © 2024 作者。由 Wolters Kluwer Health, Inc. 出版

Oligometastatic prostate cancer (OmPCa) is characterized by a restricted number of metastatic lesions confined to a limited organ range, presenting a distinct clinical challenge. The role of cytoreductive prostatectomy (CRP) in managing this specific metastatic stage has gained attention but remains controversial. This study aims to assess the effectiveness of CRP in OmPCa by synthesizing outcomes from previous studies and analyzing data from a multicenter, retrospective cohort.We focused on evaluating overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and castration-resistant prostate cancer-free survival (CRPCFS) as primary outcomes. A multicenter comparative retrospective analysis was also conducted on OmPCa patients treated with CRP versus those receiving androgen deprivation therapy (ADT) alone from January 2008 to June 2018. We gathered and analyzed data on patient demographics, tumor characteristics, surgical outcomes, and survival metrics.The quantitative analysis included 18 studies(2 randomized controlled trial (RCT) and 16 non-RCT studies),comprising a total of 1733 patients with oligometastatic prostate cancer,this is the largest number of samples included in the same subject research at present.The pooled analysis demonstrated that cytoreductive surgery was associated with significantly improved OS (hazard ratio [HR]: 0.50, 95% confidence interval[CI]: 0.40-0.60) ,PFS (HR: 0.39, 95%[CI]: 0.27-0.51) ,CSS (HR: 0.44, 95%[CI]: 0.23-0.65) and CRPCFS (HR: 0.48, 95%[CI]: 0.36-0.59) compared to non-surgical management.In addition,OS ,PFS and CRPCFS showed better results in the CRP group in all analyses(RCT and non-RCT).Additionally,in our multicenter retrospective research analysis, 64 patients with oligometastatic prostate cancer were included ,32 underwent CRP (50%), and 32 underwent ADT alone (50%).The median follow-up time was 40.1 (18.9-51.3) months.The OS (P=0.0182), PFS (P=0.0297), and CRPCFS (P=0.0125) had statistical difference between the two matched cohorts.Moreover,we observed 8(25%) cases of perioperative complications, with the most common being urinary incontinence(9.4%).Incorporating CRP alongside ADT in the treatment protocol for OmPCa significantly enhances patient outcomes in terms of OS, PFS, and CRPC-free survival, underscoring the potential benefit of this surgical approach in the specified patient population.Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.